LRT Capital Management LLC Takes $759,000 Position in IDEXX Laboratories, Inc. $IDXX

LRT Capital Management LLC purchased a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 1,188 shares of the company’s stock, valued at approximately $759,000.

Several other hedge funds have also made changes to their positions in the stock. Bank of New York Mellon Corp boosted its position in IDEXX Laboratories by 41.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 2,056,680 shares of the company’s stock valued at $1,313,992,000 after purchasing an additional 605,290 shares during the period. Norges Bank acquired a new stake in IDEXX Laboratories in the second quarter worth $221,955,000. JPMorgan Chase & Co. lifted its stake in IDEXX Laboratories by 60.0% in the third quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock valued at $555,802,000 after buying an additional 326,348 shares during the last quarter. Schroder Investment Management Group lifted its stake in IDEXX Laboratories by 295.1% in the second quarter. Schroder Investment Management Group now owns 315,785 shares of the company’s stock valued at $169,368,000 after buying an additional 235,863 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its holdings in shares of IDEXX Laboratories by 16.7% during the third quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company’s stock valued at $840,638,000 after acquiring an additional 187,967 shares during the period. Institutional investors own 87.84% of the company’s stock.

Insider Activity

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 1,464 shares of the business’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total value of $920,299.68. Following the sale, the director directly owned 648 shares in the company, valued at approximately $407,345.76. The trade was a 69.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael G. Erickson sold 5,371 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total transaction of $3,369,657.98. Following the completion of the sale, the executive vice president directly owned 12,693 shares of the company’s stock, valued at $7,963,334.34. The trade was a 29.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 45,957 shares of company stock valued at $29,862,109 over the last quarter. Insiders own 0.98% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on IDXX shares. Weiss Ratings lowered shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, January 29th. Barclays cut their price objective on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. UBS Group reduced their target price on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a research note on Tuesday, February 3rd. Wall Street Zen cut shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Finally, Piper Sandler cut their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. Seven investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $783.33.

IDEXX Laboratories Trading Up 2.2%

NASDAQ:IDXX opened at $586.37 on Tuesday. The stock has a market cap of $46.69 billion, a price-to-earnings ratio of 44.86, a PEG ratio of 3.48 and a beta of 1.66. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $769.98. The business has a fifty day moving average of $656.25 and a 200-day moving average of $666.45.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). The company had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company’s revenue was up 14.3% on a year-over-year basis. During the same period in the prior year, the company posted $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Equities analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.